Other studies utilizing TREM2−/− mice and TREM2 inhibitors for sarcoma, colorectal, and breast cancer models have demonstrated that TREM2 deficiency leads to improved antigen presentation from TREM2−/− macrophages compared to wild type, along with improved CD8+ TIL presence and PD-1 expression, suggesting that TREM2 inhibition may be synergistic with ICI therapy [411]. Here, CD8A is linked to breast carcinoma.